Previous close | 2.1000 |
Open | 2.1000 |
Bid | 2.0700 |
Ask | 2.4700 |
Strike | 110.00 |
Expiry date | 2025-12-19 |
Day's range | 2.1000 - 2.1000 |
Contract range | N/A |
Volume | |
Open interest | 24 |
AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price).
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.